

# Human Trop-2 Monoclonal Antibody N301Q

Catalog No.: YR0019

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Sacituzumab Biosimilar

### Isotype

Human IgG1 kappa

### Immunogen

### Recommended Isotype Control(s)

### Recommended Dilution Buffer

1×PBS pH 7.0

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification


Protein A or G purification

### Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

## Validation Data

---



Human Trop-2 ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human Trop-2 (Research Grade Sacituzumab [N301Q] Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.